Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

John O'Horo, Douglas W. Challener, Ryan J. Anderson, Richard F. Arndt, Sara E. Ausman, Scott T. Hall, Alexander Heyliger, Brian D. Kennedy, Perry W. Sweeten, Ravindra Ganesh, Raymund R. Razonable

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019'. Together they form a unique fingerprint.

Medicine & Life Sciences